A Phase I Study of UGT1A1 *28/*6 Genotype-Directed Dosing of Irinotecan (CPT-11) in Korean Patients with Metastatic Colorectal Cancer Receiving FOLFIRI

Publisher： Karger

E-ISSN： 1423-0232|88|3|164-172

ISSN： 0030-2414

Source： Oncology, Vol.88, Iss.3, 2014-11, pp. : 164-172

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Colorectal Cancer

By  

Oncology, Vol. 72, Iss. 1-2, 2007-11 ,pp. : 58-63

Karger

Access to resources Recommend Favorite

Phase II Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Colorectal Cancer

By  

Oncology, Vol. 77, Iss. 3-4, 2009-09 ,pp. : 192-196

Karger

Access to resources Recommend Favorite

A Phase II Study of Clinical Outcomes of 3-Week Cycles of Irinotecan and S-1 in Patients with Previously Untreated Metastatic Colorectal Cancer: Influence of the UGT1A1 and CYP2A6 Polymorphisms on Clinical Activity

By  

Oncology, Vol. 82, Iss. 5, 2012-04 ,pp. : 290-297

Karger

Access to resources Recommend Favorite

Combination of Irinotecan (CPT-11) plus 5-Fluorouracil and Leucovorin (FOLFIRI Regimen) as First Line Treatment for Elderly Patients with Metastatic Colorectal Cancer: A Phase II Trial

By  

Oncology, Vol. 69, Iss. 5, 2005-12 ,pp. : 384-390

Karger

Access to resources Recommend Favorite

A Phase I Study of Infusional 5-Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan in Japanese Patients with Advanced Colorectal Cancer Who Harbor UGT1A1*1/*1,*1/*6 or *1/*28

By  

Oncology, Vol. 82, Iss. 4, 2012-04 ,pp. : 242-248

Karger

Access to resources Recommend Favorite